1. do Rego J-C, Suaudeau C, Chapouthier G, Costentin J. Mouse lines differing in sensitivity to b-CCM differ in tasks used for testing antidepressants. Pharmacol. Biochem. Behav. 72, 411-416 (2002).
  2. Le Cudennec C, Naudin B, do Rego J-C, Costentin J. Nociceptin/Orphanin FQ and related peptides reduce the increase in plasma corticosterone elicited in mice by an intracerebroventricular injection. Life sci. 72, 163-171 (2002).
  3. Chartrel N, Dujardin C, Anouar Y, Leprince J, Decker A, Clerens S, do Rego J-C, Vandesande F, Llorens-Cortes C, Costentin J, Beauvillain JC, Vaudry H. Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity. Proc. Nat. Acad. Sci. USA 100, 15247-15252 (2003).
  4. Fichna J, do Rego J-C, Costentin J, Chung NN, Schiller PW, Kosson P, Janecka A. Opioid receptor binding and in vivo antinociceptive activity of position 3-substituted morphiceptin analogs. Biochem. Biophys. Res. Comm. 320, 531-536 (2004).
  5. Fichna J, do Rego J-C, Kosson P, Costentin J, Janecka A. Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in third position. Biochem. Pharmacol. 69, 179-185 (2005).
  6. Kruszynski R, Fichna J, do Rego J-C, Chung NN, Schiller PW, Kosson P, Costentin J, Janecka A. Novel endomorphin-2 analogs with µ-opioid receptor antagonist activity.J. Pept. Res. 66, 125-131 (2005).
  7. Suaudeau C, do Rego J-C, Costentin J. Modifications in avoidance reactions of mice, on a second exposure to the hot plate, resist to various amnesia-inducing treatments. Cognitive Brain Research 25, 339-347 (2005).
  8. Viana A, do Rego J-C, Von Poser GL, Ferraz AF, Heckler AP, Costentin J, Rates SM. The antidepressant-like effect of Hypericum caprifoliatum Cham & Schlecht (Gutiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake. Neuropharmacology 49, 1042-1052 (2005).
  9. do Rego J-C, Chatenet D, Orta MH, Naudin B, Le Cudennec C, Leprince J, Scalbert E, Vaudry H, Costentin J. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology 183, 103-117 (2005).
  10. Kruszynski R, Fichna J, do Rego J-C, Janecki T., Kosson P., Costentin J., Janecka A. Synthesis and biological activity of N-methylated analogs of endomorphin-2. Bioorg. Med. Chem. 13, 6713-6717 (2005).
  11. Janecka A, Fichna J, Kruszynski R, Sasaki Y, Ambo A, Costentin J, do Rego J-C. Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. Biochem. Pharmacol. 71, 188-195 (2005).
  12. do Rego J-C, Viana FA, Le Maitre E, Deniel A, Leroux-Nicolet I, Costentin J. Comparisons between anxiety tests for selection of anxious and non anxious mice. Behavioral Brain Research 169, 282-288 (2006)
  13. Chartrel N, Bruzzone F, Leprince J, Tollemer H, Anouar Y, do Rego J-C, Segalas-Milazzo I, Guilhaudis L, Cosette P, Jouenne T, Simonnet G, Vallarino M, Beauvillain JC, Costentin J, Vaudry H. Structure and functions of the novel hypothalamic RFamide neuropeptides R-RFa and 26RFa in vertebrates. Peptides 27, 1110-1120 (2006).
  14. Fichna J, do Rego J-C, Kosson P, Costentin J, Janecka A. [35S]GTPgS binding stimulated by endomorphin-2 and morphiceptin analogs. Biochem. Biophys. Res. Comm. 345, 162-168 (2006).
  15. Fichna J, Janecka A, Bailly L, Marsais F, Costentin J, do Rego J-C. In vitro characterization of novel peptide inhibitors of endomorphin-degrading enzymes in the rat brain. Chem. Biol. Drug Des. 68, 173-175 (2006)
  16. do Rego J-C, Leprince J, Chartrel N, Vaudry H, Costentin J. Behavioral effects of 26RFamide and related peptides. Peptides 27, 2715-2721 (2006).
  17. Viana A, do Rego J-C, Munari L, Dourmap N, Heckler AP, Von Poser GL, Costentin J, Rates MKS. Hypericum caprifoliatum (Guttiferae) Cham. & Schldl. : a species native to south Brazil with antidepressant like activity. Fund. Clin. Pharmacol. 20, 507-514 (2006).
  18. Le Marec O, Dubessy C, do Rego J-C, Nosjean O, Audinot V, Boutin JA, Chartrel N, Guilhaudis L, Segalas-Milazzo I, Davoust D, Tena-Sempere M, Costentin J, Vaudry H, Tonon MC, Leprince J. Agonist and antagonist activities of peptides related to 26RFa, the last member of the RFamide peptide superfamily. Peptides 2006, Edts K. Rolka, P. Rekowski & J. Silberring (Proceeding of the Twenty-Ninth European Peptide Symposium, Kenes International, Geneva, Switzerland, pp 378-379 (2006).
  19. Fichna J, Janecka A, Piestrzeniewicz M, Costentin J, do Rego J-C. Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 32, 813-821 (2007).
  20. Fichna J, do Rego J-C, Chung NN, Lemieux C, Schiller PW, Poels J, Broek JV, Costentin J, Janecka A. Synthesis and characterisation of potent and selective µ-opioid receptor antagonists, [Dmt1,D-2-Nal4]endomorphin-1 (antanal-1) and [Dmt1, D-2-Nal4]endomorphin-2 (antanal-2). J. Med. Chem. 50, 512-520 (2007).
  21. Fichna J, Janecka A, Costentin J, do Rego J-C. The endomorphin system and its evolving neurophysiological role. Pharmacol. Rev. 59, 88-123 (2007).
  22. do Rego J-C, Orta M-H, Leprince J, Tonon M-C, Vaudry H, Costentin J. Pharmacological characterization of the receptor mediating anorexigenic action of the octadecaneuropeptide ODN. Evidence for an endozepinergic tone regulating food intake. Neuropsychopharmacology 32, 1641-1648 (2007).
  23. do Rego J-C, Naïma B, Chosson E, Zahia K, Seguin E, Costentin J. Antidepressant-like effect of hyperfoliatin, a polyisoprenylated phloroglucinol derivative from Hypericum perfoliatum (Clusiaceae) is associated with an inhibition of neuronal monoamines uptake. Eur. J. Pharmacol. 569, 197-203 (2007).
  24. Fichna J, do Rego J-C, Janecki T, Staniszewska R, Poels J, Broeck JV, Costentin J, Schiller PW, Janecka A. Novel highly µ-opioid receptor antagonist based on endomorphin-2 structure. Bioorg. Med. Chem. Lett. 18, 1350-1353 (2008).
  25. Fichna J, do Rego J-C, Chung NN, Costentin J, Schiller PW, Janecka A. [Dmt1,D-1-Nal3]morphiceptin, a novel opioid peptide analog with high analgesic activity. Peptides 29, 633-638 (2008).
  26. do Rego J-C, Leprince J, Scalbert E, Vaudry H, Costentin J. Behavioral actions of urotensin II. Peptides 29, 838-844 (2008).
  27. Viana A, Rates SM, Naudin B, Janin F, Costentin J, do Rego J-C. Effect of acute or three days treatments by two established antidepressants or an extract of Hypericum caprifoliatum Cham & Schltdt (Guttiferae) on basal and stress-induced increase in serum and brain corticosterone levels. J. Psychopharmacology 22, 681-690 (2008).
  28. Fetissov S, Hamze Sinno M, Coquerel Q, do Rego J-C, Coëffier M, Gilbert D, Hökfelt T, Déchelotte P. Emerging role of autoantibodies appetite-regulating neuropeptides in eating disorders. Nutrition 24, 854-859 (2008).
  29. Mounien L, do Rego J-C, Bizet P, Boutelet I, Gourcerol G, Fournier A, Brabet P, Costentin J, Vaudry H, Jegou S. Pituitary Adenylate Cyclase-Activating Polypeptide inhibits food intake through activation of the hypothalamic melanocortin system. Neuropsychopharmacology 34, 424-435 (2009).
  30. Hamze Sinno M, do Rego J-C, Coëffier M, Bole-Feysot C, Ducrotté P, Gilbert D, Tron F, Costentin J, Hökfelt T, Déchelotte P, Fetissov S. a-Melanocyte-stimulating hormone autoantibodies regulate food intake and anxiety in rats.Psychoneuroendocrinology 34, 140-149 (2009).
  31. Perlikowska R, Gach K, Fichna J, Toth G, Walkowiak B, Bonnet J-J, do Rego J-C, Janecka A. Biological activity of endomorphin analogs with praline surrogates in position 2. Bioorg. Med. Chem. 17, 3789-3794 (2009).
  32. Fichna J, Staniszewska R, Gach K, do Rego J-C, Cravezic A, Bashashati M, Li K, Schicho R, Bonnet J-J, Janecka A, Storr AM. The novel endomorphin degradation blockers Tyr-Pro-DclPhe-Phe-NH2 (EMDB-1) and Tyr-Pro-Ala-NH2 (EMDB-2) prolong endomorphin-2 action in rat ileum in vitro. Chem. Biol. Drug Des. 76, 77-81 (2010).
  33. Condamine E, Courchay K, do Rego J-C, Leprince J, Mayer C, Davoust D, Costentin J, Vaudry H. Structural and pharmacological characteristics of chimeric peptides derived from peptide E and beta-endorphin reveal the crucial role of the C-terminal YGGFL and YKKGE motifs in their analgesic properties. Peptides 31, 962-972 (2010).
  34. Perlikowska R, Fichna J, Wyrebska A, Poels J, Vanden Broeck J, Toth G, Storr M, do Rego J-C, Janecka A. Design, synthesis and pharmacological characterization of endomorphin analogs with non-cyclic amino acid residues in position 2. Basic Clin Pharmacol. Toxicol. 106, 106-113 (2010).
  35. Fichna J, Gach K, Perlikowska R, Cravezic A, Bonnet J-J, do Rego J-C, Janecka A, Storr MA. Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract. Regul. Pept. 162, 109-114 (2010).
  36. Perlikowska R, do Rego J-C, Cravezic A, Fichna J, Wyrebska A, Toth G, Janecka A. Synthesis and biological evaluation of cyclic endomorphin-2 analogs. Peptides 31, 339-345 (2010).
  37. Gach C, do Rego J-C, Fichna J, Storr M, Delbro D, Toth G, Janecka A. Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. Peptides 31, 1617-1624 (2010).
  38. Vaudry H, do Rego J-C, Le Mevel JC, Chatenet D, Tostivint H, Fournier A, Tonon MC, Pelletier G, Conlon JM, Leprince J. Urotensin II, from fish to human. Ann. NY Acad. Sci. 1200, 53-66 (2010).
  39. Cravezic A, Fichna J, Gach K, Wyrebska A, Perliskowska R, Costentin J, Bonnet JJ, Janecka A, do Rego J-C. Effect of potent endomorphin degradation blockers on analgesic and antidepressant-like responses in mice. Neuropharmacology 61, 1229-1238 (2011).
  40. Le Marec O, Neveu C, Lefranc B, Dubessy C, Boutin J, do Rego J-C, Costentin J, Tonon MC, Tena-Sempere M, Vaudry H, Leprince J. Structure-activity relationships of a series of the RFamide-related peptide 26RFa. J. Med. Chem. 54, 4806-4814 (2011).
  41. Fichna J, Perlikowska R, Wyrebska A, Gach K, Piekielna J, do Rego J-C, Toth G, Janecki T, Janecka A. Effect of 2’,6’-dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs. Bioorg. Med. Chem. 19, 6977-6981 (2011).
  42. Stein A-C, Viana AF, Müller LG, Nunes JM, Stolz ED, do Rego J-C, Costentin J,  von Poser GL, Rates SMK. Uliginosin B, a phloroglucinol derivative from Hypericum polyanthemum: A promising new molecular pattern for the development of antidepressant drugs. Behav. Brain Res. 228, 66-73 (2012).
  43. Garcia FD, Coquerel Q, do Rego J-C, Cravezic A, Bole-Feysot C, Kiive E, Déchelotte P, Harro J, Fetissov SO. Anti-neuropeptide Y plasma immunoglobulins in relation to mood and appetite in depressive disorder. Psychoneuroendocrinology 37, 1457-1467 (2012).
  44. Stolz ED, Viana AF, Hasse DR, von Poser GL, do Rego J-C, Rates SMK. Uliginosin B presents antinociceptive effect mediated by dopaminergic and opioid systems in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 39, 80-87 (2012).
  45. Perlikowska R, Fichna J, do Rego J-C, Gach K, Janecka A. Kinetic studies of novel inhibitors of endomorphin degrading enzymes. Med. Chem. Res. 21, 1445-1450 (2012).
  46. Neveu C, Lefranc B, Tasseau O, do Rego J-C, Bourmaud A, Chan P, Bauchat P, Le Marec O, Chuquet J, Guilhaudis L, Boutin JA, Ségalas-Milazzo I, Costentin J, Vaudry H, Baudy-Floc'h M, Vaudry D, Leprince J. Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza-β3-pseudopeptide agonist. J. Med. Chem. 55, 7516-7524 (2012).
  47. Braga A, Stein AC, Dischkaln Stolz E, Dallegrave E, Buffon A, do Rego J-C, Gosmann G, Fialho Viana A, Kuze Rates SM. Repeated administration of an aqueous spray-dried extract of the leaves of Passiflora alata Curtis (Passifloraceae) inhibits body weight gain without altering mice behavior. J. Ethnopharmacol. 145, 59-66 (2013).
  48. Mayeur A, Duclos C, Honoré A, Gauberti M, Drouot L, do Rego J-C, Bon-Mardion N,Jean L, Vérin E, Emery E, Lemarchant S, Vivien D, Boyer O, Marie JP, Guérout N. Potential of olfactory unsheathing cells from different sources for spinal cord repair. PLoS One. 8, 1-12 (2013).
  49. Takagi K, Legrand R, Asakawa A, Amitani H, François M, Tennoune N, Coëffier M,Claeyssens S, do Rego J-C, Déchelotte P, Inui A, Fetissov SO. Anti-ghrelin immunoglobulins modulate ghrelin stability and its orexigenic effect in obese mice and humans. Nat. Commun. 4 :2685, 1-11 (2013).
  50. Perlikowska R, Piekielna J, Fichna J, do Rego J-C, Toth G, Janecki T, Janecka A. Pharmacological Properties of Novel Cyclic Pentapeptides with µ-opioid Receptor Agonist Activity. Med Chem. 10, 154-61 (2014).
  51. Jésus P, Ouelaa W, François M, Riachy L, Guérin C, Aziz M, do Rego J-C,Déchelotte P, Fetissov SO, Coëffier M. Alteration of intestinal barrier function during activity-based anorexia in mice. Clin. Nutr. 33, 1046-1053 (2014).
  52. Lemarchant S, Pruvost M, Hébert M, Gauberti M, Hommet Y, Briens A, Maubert E, Gueye Y, Féron F, Petite D, Mersel M, do Rego JC, Vaudry H, Koistinaho J, Ali C, Agin V, Emery E, Vivien D. tPA promotes ADAMTS-4-induced CSPG degradation, thereby enhancing neuroplasticity following spinal cord injury. Neurobiol. Dis. 66, 28-42 (2014).
  53. Coquerel D, Neviere R, Delile E, Mulder P, Marechal X, Montaigne D, Renet S, Remy-Jouet I, Gomez E, Henry JP, do Rego JC, Richard V, Tamion F. Gene deletion of protein tyrosine phosphatase 1B protects against sepsis-induced cardiovascular dysfunction and mortality. Arterioscler Thromb. Vasc. Biol. 34, 1032-44 (2014).
  54. Perlikowska R, Malfacini D, Cerlesi MC, Calo' G, Piekielna J, Floriot L, Henry T, do-Rego JC, Tömböly C, Kluczyk A, Janecka A. Pharmacological characterization of endomorphin-2-based cyclic pentapeptides with methylated phenylalanine residues. Peptides 55, 145-50 (2014).
  55. Sałaga M, Polepally PR, Sobczak M, Grzywacz D, Kamysz W, Sibaev A, Storr M, Do Rego JC, Zjawiony JK, Fichna J. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. J. Pharmacol. Exp. Ther. 350, 69-78 (2014).
  56. Aligny C, Roux C, Dourmap N, Ramdani Y, Do-Rego JC, Jégou S, Leroux P, Leroux-Nicollet I, Marret S, Gonzalez BJ. Ketamine alters cortical integration of GABAergic interneurons and induces long-term sex-dependent impairments in transgenic Gad67-GFP mice. Cell. Death. Dis. 5, e1311. doi: 10.1038/cddis.2014.275 (2014).
  57. Perlikowska R, Piekielna J, Mazur M, Koralewski R, Olczak J, do Rego JC, Fichna J, Modranka J, Janecki T, Janecka A. Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2. Bioorg. Med. Chem. 22, 4803-4809 (2014).
  58. Tennoune N, Chan P, Breton J, Legrand R, Chabane YN, Akkermann K, Järv A, Ouelaa W, Takagi K, Ghouzali I, Francois M, Lucas N, Bole-Feysot C, Pestel-Caron M, do Rego JC, Vaudry D, Harro J, Dé E, Déchelotte P, Fetissov SO. Bacterial ClpB heat-shock protein, an antigen-mimetic of the anorexigenic peptide α-MSH, at the origin of eating disorders. Transl. Psychiatry 4:e458. doi: 10.1038/tp.2014.98 (2014).
  59. Gach K, Belkacemi O, Lefranc B, Perlikowski P, Masson J, Walet-Balieu ML, Do-Rego JC, Galas L, Schapman D, Lamtahri R, Tonon MC, Vaudry D, Chuquet J, Leprince J. Detection, characterization and biological activities of [bisphospho-thr3,9]ODN, an endogenous molecular form of ODN released by astrocytes. Neuroscience 290, 472-84 (2015).
  60. Tennoune N, Legrand R, Ouelaa W, Breton J, Lucas N, Bole-Feysot C, do Rego JC, Déchelotte P, Fetissov SO. Sex-related effects of nutritional supplementation of Escherichia coli: relevance to eating disorders. Nutrition 31, 498-507 (2015).
  61. François M, Barde S, Achamrah N, Breton J, do Rego JC, Coëffier M, Hökfelt T, Déchelotte P, Fetissov SO. The number of preproghrelin mRNA expressing cells is increased in mice with activity-based anorexia. Neuropeptides 51, 17-23 (2015).
  62. Piekielna J, Perlikowska R, do-Rego JC, do-Rego JL, Cerlesi MC, Calo G, Kluczyk A, Łapiński K, Tömböly C, Janecka A. Synthesis of mixed opioid affinity cyclic endomorphin-2 analogues with fluorinated phenylalanines. ACS Med. Chem. Lett. 6, 579-83 (2015).
  63. Lecointre M, Vézier C, Bénard M, Ramdani Y, Dupré N, Brasse-Lagnel C, Henry VJ, Roy V, Marret S, Gonzalez BJ, Jégou S, Leroux-Nicollet I. Age-dependent alterations of the NMDA receptor developmental profile and adult behavior in postnatally ketamine-treated mice. Dev. Neurobiol. 75, 315-33 (2015).
  64. Lacaille H, Duterte-Boucher D, Liot D, Vaudry H, Naassila M, Vaudry D. Comparison of the deleterious effects of binge drinking-like alcohol exposure in adolescent and adult mice. J. Neurochem. 132, 629-41 (2015).
  65. Pelloux Y, Costentin J, Duterte-Boucher D. Differential involvement of anxiety and novelty preference levels on oral ethanol consumption in rats. Psychopharmacology (in press) (2015).
  66. Salaga M, Polepally PR, Zielinska M, Marynowski M, Fabisiak A, Murawska N, Sobczak K, Sacharczuk M, Do Rego JC, Roth BL, Zjawiony JK, Fichna J. Salvinorin A analogs PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice. Br. J. Pharmacol. (in press), doi: 10.1111/bph.13212 (2015).